Argus upgrades Regeneron stock to Buy with USD 850.00 target

Published on 10/06/2026 at 13:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi alliance brings Regeneron USD 1.0 billion upfront. Regeneron stock costs EUR 648.60 on October 6, 2026 versus EUR 647.25.

Pop-Art-Comic-Illustration eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor — Regeneron Pharma US75886F1075 präsentiert eine farbenfrohe Pop-Art-Comic-Szene eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor, Illustration mit AI erstellt.

Argus upgraded Regeneron stock from Hold to Buy and set a USD 850.00 price target on October 1, 2026, according to MarketBeat. Regeneron was trading at EUR 648.60 at Lang & Schwarz on October 6, 2026 at 1:04 p.m. CEST, up 0.21 percent versus the prior close of EUR 647.25 on October 5, 2026.

Sanofi alliance adds USD 1.0 billion

Regeneron and Sanofi expanded their antibody collaboration on October 1, 2026, adding four next-generation, long-acting antibodies to the alliance. The company will receive USD 1.0 billion upfront and could receive up to USD 7.0 billion in development, regulatory and commercial milestone payments, according to Regeneron.

The companies will share development and commercialization costs and split future profits from the potential products equally worldwide. REGN20423 is already in a Phase 1 trial for atopic dermatitis, while the other three antibodies are expected to enter clinical studies in 2027, the release said.

Second-quarter figures beat consensus

For the second quarter of 2026, Regeneron reported adjusted earnings per share of USD 14.29 against a USD 10.16 consensus estimate. That result was USD 4.13, or 40.65 percent, above consensus, while revenue reached USD 4.29 billion versus USD 3.82 billion expected, according to MarketBeat.

Revenue increased 16.70 percent from the year-earlier quarter. For investors, the key test is whether the expanded immunology pipeline can complement the established business while the company prepares its next report.

October 30 sets the next date

Regeneron will report third-quarter 2026 financial and operating results before U.S. markets open on October 30, 2026, with a conference call scheduled for 8:30 a.m. ET, according to Regeneron. The release will give investors a fresh read on product demand, pipeline progress and the financial contribution expected from the Sanofi agreement.

At Lang & Schwarz, Regeneron stock was trading at EUR 648.60 on October 6, 2026 at 1:04 p.m. CEST, plus 0.21 percent versus the prior close of EUR 647.25 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.